CSL-VIFOR
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221127005020/en/
CSL Vifor and Fresenius Kabi today announced that China’s National Medical Products Administration (NMPA) has approved Ferinject®, a preparation for intravenous iron therapy for the treatment of iron deficiency in adult patients for whom oral iron preparations are ineffective, oral iron preparations cannot be used or for whom there is a clinical need to deliver iron rapidly. Ferinject® has now received marketing authorization in 85 countries worldwide.
“We are thrilled about the marketing authorization of Ferinject®, which is a milestone for Chinese patients living with iron deficiency or iron deficiency anemia”, said Hervé Gisserot, General Manager of CSL Vifor. “There is a high unmet need in China, which has the world’s largest iron deficiency population, and we are confident that Ferinject® can make a meaningful difference in the treatment of these patients. At the same time, this is another important step in our goal to globalizing and maximizing the performance of our iron franchise as we look forward to bring this treatment to market as soon as possible.”
“Marketing authorization of Ferinject® will strengthen our commitment of bringing innovative medicines for patients in China. We are guided by our corporate philosophy of caring for life and invested to putting essential medicines and technologies in the hands of people who help patients and to finding the best answers to the challenges they face”, said Yang Weiping, President of Fresenius Kabi China.
The approval of Ferinject® may also enable a more effective implementation of PBM in Chinese hospitals, where an estimated 3-4 million patients undergo elective surgery each year. In China, PBM encompasses multiple in-hospital procedures across therapeutic areas. The China National Health Commission (NHC) has announced guidelines for perioperative PBM as a health standard across China, effective as per 1 June 2022.
Marketing authorization in China is based on positive clinical results from the phase-III trial VIT-IRON-2011-004. This open label, randomized multicenter study showed that Ferinject® is an effective and well-tolerated alternative to iron sucrose for the treatment of iron deficiency anemia that can provide an improved hemoglobin response and correction of iron deficiency in Chinese patients.
CSL Vifor and Fresenius Kabi currently expect to begin to market Ferinject® in the first half of 2023, with National Reimbursement Drug List (NRDL) listing anticipated in January 2024.
About CSL Vifor
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.
About Fresenius Kabi
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.
With its corporate mission of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face. For more information, please visit www.fresenius-kabi.com.
About Ferinject®
Ferinject®/Injectafer® (ferric carboxymaltose) is an i.v. iron therapy with market authorization in 85 countries by November 2022. More than 19 million patient years of experience have helped to establish Ferinject®/ Injectafer® as a trusted brand, with clinical benefits demonstrated by its efficacy and safety data2. Ferinject’s® quality relies on a consistent and firmly-controlled manufacturing process based on decades of experience.
About iron deficiency
Iron Deficiency affects about half of the patients with chronic kidney disease3 and chronic heart failure and is associated with reduced quality of life4, an increased risk of hospitalization5 and cardiovascular death6. Despite the serious consequences and high prevalence, of iron deficiency, the condition remains under-recognized7.
Iron plays a vital role in many bodily processes, including the production of red blood cells, effective heart and brain function, and the prevention of infection and illness. Without enough iron, the body is unable to function properly. Common symptoms include fatigue, dizziness, and shortness of breath. Iron deficiency and iron deficiency anemia is estimated to affect one in three people worldwide8, yet despite the serious consequences and high prevalence9, it remains an under-recognized condition.
Although iron deficiency can affect anyone, it is most prevalent in premenopausal women, pregnant woman and children under five10. Left untreated, it can develop into iron deficiency anemia. The effects of iron deficiency differ from person to person but can be linked to an overall decline in general health and well-being11. Even without anemia, iron deficiency can be debilitating, exacerbate an underlying chronic disease and lead to increased morbidity and mortality12. Common symptoms include fatigue11, 13, 14 pale skin13, brittle nails13, 15, craving non-food items such as dirt, clay and ice16, and an inability to concentrate11, 17. In children, iron deficiency can significantly impair cognitive and motor development18.
About Patient Blood Management (PBM)
PBM is designed to improve surgical and medical patient outcomes by optimally managing and preserving patients’ blood. Proactive identification and treatment of iron deficiency anemia in patients scheduled for elective surgery has been associated with a reduced need for blood transfusion19 , reduced length of hospital stay19, improved patient’s outcomes20, and overall healthcare expenditure reduction21.
References:
1. Ni W, Yuan X, Sun Y, et al. Anaemia and associated factors among older adults in an urban district in China: a large-scale crosssectional study. BMJ Open 2022;12:e056100. doi:10.1136/ bmjopen-2021-056100.
2. Scott Drugs. 2018 Mar;78(4):479–493. doi: 10.1007/ s40265-018-0885-7.
3. Wong MMY et al. Clin Kid J 2019:1–12; Rocha BML, et al. J Am Coll Cardiol. 2018;71(7):782–793.
4. Guedes M NDT 2021. doi: 10.1093/ndt/gfab050; Enjuanes C, et al. Int J Cardiol. 2014;174(2):268–275.
5. Guedes et al. J Am Soc Nephrol. 2021 Aug;32(8):2020-2030, Martens P, et al. Acta Cardiol. 2018;73(2):115–123.
6. Guedes et al. J Am Soc Nephrol. 2021 Aug;32(8):2020-2030; Klip IT, et al. Am Heart J. 2013;165:575–82.e3.
7. Eur J Heart Fail. 2021 Sep 3. doi: 10.1002/ejhf.2338.
8. Peyrin-Biroulet L, et al. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585-94.
9. World Health Organization. Worldwide prevalence of anaemia 1993-2005. 2008. Available at URL: http://apps.who.int/iris/bitstream/handle/10665/43894/9789241596657_eng.pdf;jsessionid=9C613E2F4D481EDEB9DE07986AFCE0C7?sequence=1. Last accessed: June 2018.
10. Hercberg S, et al. Iron deficiency in Europe. Public Health Nutr. 2007;4(2b).
11. Fernando B, et al. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol. 2009 Oct 7; 15(37): 4638-4643.
12. Cappellini MD et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol. 2017 Oct;92(10):1068-1078.
13. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31-38.
14. Favrat, B., et al. (2014). Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. PLoS One 9(4): e94217. eCollection 2014.
15. Cashman MW, Sloan SB. Nutrition and nail disease. Clin Dermatol. 2010;28(4):420-5.
16. Barton JC, et al. Pica associated with iron deficiency or depletion: clinical and laboratory correlates in 262 non-pregnant adult outpatients. BMC Blood Disord. 2010;10:9. doi:10.1186/1471-2326-10-9.
17. Patterson A et al. Iron deficiency, general health and fatigue: Results from the Australian Longitudinal Study on Women’s Health. Qual Life Res. 2000;9:491-497.
18. World Health Organization. Nutritional anaemias: tools for effective prevention and control. 2017. Available at URL: http://www.who.int/nutrition/publications/micronutrients/anaemias-tools-prevention-control/en/. Last accessed: June 2018.
19. Froessler B. et al., Ann Surg 2016
20. Kotzé A. et al., British Journal of Anaesthesia 2012
21. Basora M. et al., Blood Transfus 2018
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221127005020/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cooler Master Expands the MasterFrame Series with the Compact and Modular MasterFrame 400 Mesh12.11.2025 13:07:00 CET | Press release
The New PC Case Combines Modular Flexibility with a Clean Design for Easy Builds and Polished Final Look Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced the MasterFrame 400 Mesh, a compact PC case that brings the signature MasterFrame design language to a more accessible, desk-friendly format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112507322/en/ MasterFrame 400 Mesh shown with V4 3DHP air cooler. The MasterFrame 400 Mesh delivers FreeForm 2.0 modularity in a simplified build experience. It offers dual orientation for vertical or horizontal setups, repositionable brackets, and mesh-optimized airflow so builders can tailor layout and thermals with confidence. The result is a compact footprint that still supports serious hardware. The case is engineered for Micro-ATX and Mini-ITX systems and supports high-performance components without compromise. Builders can install GPU
IonQ to Highlight Real-World Quantum Applications at Web Summit 202512.11.2025 13:05:00 CET | Press release
IonQ’s Dr. Chris Ballance to speak on how fidelity breakthroughs are accelerating practical use cases and quantum advantage IonQ (NYSE: IONQ), the world’s leading quantum company, today announced its participation in Web Summit 2025, one of the largest technology events in Europe. IonQ’s President of Quantum Computing and co-founder of Oxford Ionics, Dr. Chris Ballance, is scheduled to speak during the conference’s AI Summit on Thursday, November 13, 2025, at 10:30 AM local time. The AI Summit session, “Quantum Without Compromise: The Race to Real-world Applications,” will be moderated by technology journalist, Mary-Ann Russon. The discussion will focus on IonQ’s recent breakthroughs in quantum gate fidelity and how these advancements underpin the company’s roadmap toward fault-tolerant systems. Dr. Ballance will also share how these engineering accomplishments translate into quantum computing’s growing impact across industries. “We’re at a pivotal moment where breakthroughs in quantum
Ananda Scientific and Benta Sign Memorandum on Advancing Treatments for PTSD12.11.2025 13:04:00 CET | Press release
Ananda Scientific Inc., a clinical-stage drug development company advancing innovative therapies for high-impact neuropsychiatric disorders, today announced the signing of a Memorandum of Understanding (MOU) with Benta SAS. The MOU expresses the parties’ intent to explore a potential collaboration focused on accelerating the development and future availability of a new treatment for Post-Traumatic Stress Disorder (PTSD) in Europe and the Middle East/North Africa (MENA) region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112416172/en/ PTSD is a chronic and debilitating condition that affects millions of people worldwide. Despite its significant prevalence and devastating impact on patients, families, and communities, there has been no new approved drug for PTSD in over two decades — underscoring a critical unmet medical need. As part of its clinical development pipeline, Ananda Scientific is currently advancing Nantheia
Global Airline Reliability Improves in October, Led by Asia-Pacific as North America Faces Operational Pressures; Cirium Analysis12.11.2025 13:00:00 CET | Press release
Cirium, the world’s most trusted source of aviation analytics, has published its October 2025 On-Time Performance (OTP) Report, covering more than 370,000 flights with 99.8% global coverage. The data indicates a 26% reduction in global cancellations compared with September, reflecting improved operational stability across the commercial aviation network. The results also highlight distinct regional dynamics shaping airline performance worldwide. Asia-Pacific carriers led the recovery, cutting flight cancellations by 43% as airlines across Japan, South Korea, and the Philippines strengthened network performance and capacity. Notably, the world’s top-performing airports in October — Harbin Taiping and Changchun Longjia in China, and Kaohsiung International in Taiwan — were all located in the region, underscoring its continued operational gains and steady recovery momentum. North American operations showed greater operational strain, with flight cancellations rising by about 12.6% month o
New Study Further Validates Environmental Benefits of Floor Refinishing Compared to Replacement12.11.2025 12:00:00 CET | Press release
Renovation of hard flooring surfaces, such as wood and resilient, saves up to 92 percent in CO2 emissions and up to 98 percent in energy usage A recent report and lifecycle assessment (LCA) conducted by IVL Swedish Environmental Research Institute confirms refinishing hard flooring surfaces, including wood, vinyl and linoleum, is more sustainable for the environment than replacing the flooring surfaces. This new study, which was conducted for the German market, is the next step of research inspired from a previous 2019 study conducted in Sweden. Both studies aim to evaluate the environmental impact of replacing a worn, damaged or outdated flooring surface compared to refinishing the flooring surface which may include sanding, finishing, staining, or painting. Bona, a global, family-owned company that supplies products for installing, renovating, maintaining, and restoring premium floors, commissioned this new study to build on the findings from a 2019 Swedish study. The new research fo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom